NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Recruiting | N/A | 1500 | Europe, RoW | There are no interventions as the study is purely observational. | European Society of Cardiology | Spontaneous Coronary Artery Dissection | 10/26 | 10/27 | | |
EUROSHOCK, NCT03813134: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock |
|
|
| Recruiting | N/A | 428 | Europe | Percutaneous coronary intervention (PCI), Pharmacological Support, VA-ECMO, Veno-Arterial Extra Corporeal Membrane Oxygenation. | University of Leicester, European Commission, University of Glasgow, KU Leuven, University of East Anglia, Deutsches Herzzentrum Muenchen, A.O. Ospedale Papa Giovanni XXIII, Chalice Medical Ltd, Ludwig-Maximilians - University of Munich, University of Tromso, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Paula Stradina Liniska Universitates, Accelopment AG, Universiteit Antwerpen, Cardiovascular European Research Centre (CERC) | Cardiogenic Shock | 03/23 | 02/24 | | |
PROCTOR, NCT03805048: PeRcutaneous cOronary Intervention of Native Coronary arTery Versus Venous Bypass Graft in Patients With Prior CABG |
|
|
| Recruiting | N/A | 584 | Europe | Percutaneous coronary intervention | Amsterdam UMC, location VUmc | Coronary Artery Disease | 12/26 | 06/27 | | |
